RETA 30mg

For Research Purposes Only. Not intended for human consumption.

RETA (Retatrutide) is a triple agonist peptide targeting GIP, GLP-1, and glucagon receptors simultaneously. It represents one of the most advanced classes of metabolic research peptides currently under investigation, with Phase 2 clinical trial data demonstrating significant effects on body weight and metabolic markers.

Research Overview

Retatrutide’s triple receptor agonism mechanism differentiates it from dual agonists. Research has focused on its effects on adipose tissue reduction, energy expenditure, hepatic fat content, and broader metabolic regulation. Its well-documented pharmacological profile makes it a significant subject of ongoing metabolic research.

Key Research Areas

• Triple GIP/GLP-1/glucagon receptor agonism mechanisms
• Adipose tissue reduction and energy expenditure research
• Hepatic steatosis and liver fat research models
• Metabolic syndrome pathway investigation
• Comparative receptor pharmacology studies

Product Specifications

• Form: Lyophilized powder
• Purity: ≥98% (HPLC verified)
• Quantity: 30mg per vial
• Testing: Independent third-party COA available
• Storage: Store at -20°C. Stable at 4°C short-term.

Zyvara Labs Quality Standard

Every batch independently tested via HPLC and mass spectrometry. Lot-specific COAs available on this page.

For laboratory research purposes only. Not approved for human or veterinary use.

The information provided here is for educational and research purposes only. All studies referenced are preclinical or in vitro unless otherwise noted. This product has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any condition.

Researchers should review all available literature and consult appropriate regulatory guidelines before use. Certificate of Analysis documents for each lot are available in our COA Library.